The Role of Integrated F-18-FDG-PET Scanning in the Detection of M1 Disease in Oesophageal Adenocarcinoma and Impact on Clinical Management

Journal of Gastrointestinal Surgery

Volumn 15, Issue 12, 2011, Pages 2127-2135

  Vyas, Soumil ^a   Markar, Sheraz R ^a   Iordanidou, Lydia ^a   Read, Samantha ^a   Stoker, David ^a   Hashemi, Majid ^a   Mitchell, Ian ^a   Winslet, Mark ^a   Bomanji, Jamshed ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

FDG PET scans; Oeosphageal cancer; Synchronous malignancies

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; COLON TUMOR; ESOPHAGUS TUMOR; EVALUATION; FEMALE; HUMAN; MALE; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; SCINTISCANNING; SECOND CANCER; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 81355146670     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-011-1686-4     Document Type: Article

References (48)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-6.
2. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of oesophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
3. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 549-55.
4. El-Serag HB. The epidemic of oesophageal adenocarcinoma. Gastroenterol Clin North Am 2002; 31: 421-40.
5. Stein HJ, Brücher BL, Sendler A, Siewert JR. Esophageal cancer: patient evaluation and pre-treatment staging. Surg Oncol. 2001 Nov; 10(3): 103-11. Review.
6. Pfau PR, Perlman SB, Stanko P, Frick TJ, Gopal DV, Said A, Zhang Z, Weigel T. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc. 2007 Mar; 65(3): 377-84.
7. Omloo JM, Sloof GW, Boellaard R, Hoekstra OS, Jager PL, van Dullemen HM, Fockens P, Plukker JT, van Lanschot JJ. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy. 2008 Jun; 40(6): 464-71.
8. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for esophageal cancer: a meta-analysis. Br J Cancer. 2008 Feb 12; 98(3): 547-57. Epub 2008 Jan 22.
9. MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009; 91(1): 85-94.
10. Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan TS, Macapinlac HA, Erasmus JJ. PET/CT of esophageal Cancer: its role in clinical management. Radiographics. 2007 Nov-Dec; 27(6): 1635-52. Review.
11. Liberale G, van Laethem JL, Gay F, Goldman S, Nagy N, Coppens E, Gelin M, El Nakadi I. The role of PET scan in the preoperative management of oesophageal cancer. Eur J Surg Oncol. 2004 Nov; 30(9): 942-7.
12. Flamen P, Lerut A, van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000 Sep 15; 18(18): 3202-10.
13. van Westreenen HL, Heeren PA, van Dullemen HM, van der Jagt EJ, Jager PL, Groen H, Plukker JT. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg. 2005 Jan; 9(1): 54-61.
14. Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, Jager PL, van Eck-Smit BL, Plukker JT, van Lanschot JJ, Sloof GW. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology. 2005 Sep; 236(3): 841-51. Review.
15. van Westreenen HL, Heeren PA, Jager PL, van Dullemen HM, Groen H, Plukker JT. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol. 2003 Nov; 10(9): 1100-5.
16. 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. Eur Radiol. 2011 Feb; 21(2): 274-80.
17. Gospodarowicz M, Wittekind C, Sobin L. Esophagus. In: Wittekind C, Sobin L (eds) UICC-TNM Classification of malignant tumours, 7th edn. Wiley, New York (2009).
18. 18F]fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol. 2005 Oct 20; 23(30): 7654-9.
19. Thompson WM, Halvorsen RA Jr: Staging esophageal carcinoma II: CT and MRI. Semin Oncol 21: 447-452, 1994.
20. 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004 Sep 15; 22(18): 3805-12. Review.
21. Rice TW: Clinical staging of esophageal carcinoma: CT, EUS, and PET. Chest Surg Clin N Am 10: 471-485, 2000.
22. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, Siegel BA, Cooper JD. Improvement in Staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64: 770 -7.
23. Peters JH, Hoeft SF, Heimbucher J, Bremner RM, DeMeester TR, Bremner CG, Clark GW, Kiyabu M, Parisky Y. Selection of patients for curative or palliative resection of esophageal cancer based on preoperative endoscopic ultrasonography. Arch Surg. 1994 May; 129(5): 534-9.
24. Chandawarkar RY, Kakegawa R, Fujita H, Yamana H, Hayabuthi N. Comparative analysis of imaging modalities in the preoperative assessment of nodal metastasis in esophageal cancer. J Surg Oncol 1996; 61: 214-7.
25. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Thoracoscopic staging and surgical therapy for esophageal cancer. Chest 1995; 107: 218S-23S.
26. van Westreenen HL, Westerterp M, Sloof GW, Groen H, Bossuyt PM, Jager PL, Comans EF, van Dullemen HM, Fockens P, Stoker J, van der Jagt EJ, van Lanschot JJ, Plukker JT. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg. 2007 Dec; 94(12): 1515-20.
27. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996 Dec; 23(12): 1641-74. Review.
28. 18F]-FDG in oncology: a clinical update. Nucl Med Biol 1996; 23: 717-35.
29. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000; 30: 150-185.
30. Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano H, Oriuchi N, Endo K. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005 Jan 1; 103(1): 148-56.
31. Luketich JD, Schauer PR, Meltzer CC, Landreneau RJ, Urso GK, Townsend DW, Ferson PF, Keenan RJ, Belani CP. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997 Sep; 64(3): 765-9.
32. Bar-Shalom R, Guralnik L, Tsalic M, Leiderman M, Frenkel A, Gaitini D, Ben-Nun A, Keidar Z, Israel O. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging. 2005 Aug; 32(8): 918-24. Epub 2005 Apr 19.
33. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer. 1998 Aug; 78(4): 521-7.
34. Ott K, Weber W, Siewert JR. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus. 2006; 19(6): 433-42.
35. Wallace MB, Nietert PJ, Earle C, Krasna MJ, Hawes RH, Hoffman BJ, Reed CE. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg. 2002 Oct; 74(4): 1026-32.
36. Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 2002; 137: 1001-7.
37. Bruzzi JF, Truong MT, Macapinlac H, Munden RF, Erasmus JJ. Integrated CT-PET imaging of esophageal cancer: unexpected and unusual distribution of distant organ metastases. Curr Probl Diagn Radiol 2007; 36: 21-29.
38. 18F-FDG PET in staging of patients with esophageal cancer. J Nucl Med. 2005 Aug; 46(8): 1321-5.
39. Kumagai Y, Kawano T, Nakajima Y, et al. Multiple primary cancers associated with esophageal carcinoma. Surg Today 2001; 31: 872-876.
40. Agress H Jr, Cooper BZ. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology. 2004 Feb; 230(2): 417-22. Epub 2003 Dec 29.
41. Zhuang H, Hickeson M, Chacko TK, Duarte PS, Nakhoda KZ, Feng Q, Alavi A. Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules. Clin Nucl Med. 2002 Sep; 27(9): 628-32.
42. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology. 2002 Sep; 224(3): 783-7.
43. Kagei K, Hosokawa M, Shirato H, Kusumi T, Shimizu Y, Watanabe A, Ueda M. Efficacy of intense screening and treatment for synchronous second primary cancers in patients with esophageal cancer. Jpn J Clin Oncol. 2002 Apr; 32(4): 120-7.
44. Bollschweiler E, Schloesser T, Leers J, Vallböhmer D, Schäfer H, Hölscher AH. High prevalence of colonic polyps in white males with esophageal adenocarcinoma. Dis Colon Rectum. 2009 Feb; 52(2): 299-304.
45. Meyers BF, Downey RJ, Decker PA, Keenan RJ, Siegel BA, Cerfolio RJ, Landreneau RJ, Reed CE, Balfe DM, Dehdashti F, Ballman KV, Rusch VW, Putnam JB Jr; American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg. 2007 Mar; 133(3): 738-45.
46. Heeren PA, Jager PL, Bongaerts F, van Dullemen H, Sluiter W, Plukker JT. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med. 2004 Jun; 45(6): 980-7.
47. Walker AJ, Spier BJ, Perlman SB, Stangl JR, Frick TJ, Gopal DV, Lindstrom MJ, Weigel TL, Pfau PR. Integrated PET/CT fusion imaging and endoscopic ultrasound in the pre-operative staging and evaluation of esophageal cancer. Mol Imaging Biol. 2011 Feb; 13(1): 166-71.
48. Thurau K, Palmes D, Franzius C, Minin E, Senninger N, Juergens KU, Bruewer M. Impact of PET-CT on primary staging and response control on multimodal treatment of esophageal cancer. World J Surg. 2011 Mar; 35(3): 608-16.